Immunodermatology is a medical specialization that concentrates on diagnosing and treating skin disorders characterized by responses that influence the body's immune system. Immunodermatology testing is essential in the diagnosis and treatment of many diseases afflicting the epithelial organs including the skin, intestines, respiratory tract, and mucous membranes. Skin fights antigens on T cells and produces various types of cytokines because the skin is the body's first defective organ. From newborns to the elderly, skin diseases affect patients at any time, and they can be chronic or acute, genetic or conditional, and painful or painless. Numerous factors including the surge in demand for early diagnosis of skin conditions, increase in geriatric population, enhanced health insurance, and raised disposal income are linked with the expansion of immunodermatology market size.
COVID-19 Impact analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the immunodermatology market.
Top Impacting Factors
- Increase in cases of cardiovascular diseases, surge in geriatric populations, rise in demand for minimally invasive procedure & advanced cardiovascular treatment and procedures such as balloon angioplasty are factors that drive the growth of the angioplasty balloons market
- In addition, increase in healthcare expenditure; availability of skilled professionals; collaborations & partnerships between key players to facilitate drug development; rise in R&D activities to improve quality of drugs; launch of novel developed drug in market; and technological development such as imaging technologies, drug-eluting, and cutting balloons are some factors, which boost the market growth for angioplasty balloons
- However, lack of knowledge for proper handling of the device as well as side effects and associated complications hinder the market growth.
- Contrarily, favorable reimbursement policies and support from government for regulatory approval present new pathways in the industry
Market Trends
New product launches to flourish the market
In May 2019, UCB, a global biopharmaceutical company, received FDA approval for the UCB’s tumor necrosis factor (TNF) inhibitor Cimzia (certolizumab pegol) to treat adults with moderate-to-severe plaque psoriasis. This approval indicates UCB’s path into the immuno-dermatology market.
In December 2020, Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company announced that they are focusing on the development and commercialized treatments for unmet needs in immune-mediated dermatological diseases and conditions. The robust pipeline involves 4 development programs addressing 7 dermatological diseases, which includes 3 programs in Phase 2 or Phase 3 for 5 different indications.
Key Benefits of the Report
- This study presents the analytical depiction of the immunodermatology industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the immunodermatology market share.
- The current market is quantitatively analyzed to highlight the immunodermatology market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed immunodermatology market analysis based on competitive intensity and how the competition will take shape in coming years
Questions answered in the immunodermatology Report
- Which are the leading players active in the immunodermatology market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "Immunodermatology"?
- What is "Immunodermatology" Market prediction in the future?
- Who are the leading global players in the "Immunodermatology" Market?
- What are the current trends and predicted trends?
- What are the key benefits of the "Immunodermatology" Market report?
Immunodermatology Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Diagnosis |
|
 By Therapy |
|
 By Route of Administration |
|
 By Region |
|
 Key Market Players | Astellas Pharma, Prometheus Laboratories, Abbvie, Aspen Pharmacare Inc., Glenmark Pharmaceuticals Inc., Novartis, Valeant Pharmaceuticals, Bausch Health, Taro Pharmaceuticals Inc., Novopharm Limited |
Loading Table Of Content...
